Barcode Five Rights System



Use Barcode to prevent medication errors



ADERS ® is a barcode point of care, (BPOC), solution

Request Info











Practical Compliance Solutions, Corp. helps care facilities reduce risk at the patient's bedside. Our five rights barcode solution is the easiest to implement. Our barcode point of care system can help prevent medication errors in hospitals, long term care facilities, and assisted living communities.

ADERS ® is our barcode solution for the healthcare industry. It helps eliminate medication errors by allowing caregivers to scan NDC barcodes at the patient's bedside, verifying right patient, right drug, right time, right dose, and right route of administration. For more information click the products menu or send us a web request from our Contact menu. Ask for a DEMO CD. It is the full product that is licensed for an evaluation period.

We are offering a 30 day no-obligation free trial of the ADERS ® software. Care facilities can easily determine if ADERS ® is right for them by using the software as a pilot for a single unit or ward. Click here to download a Microsoft Project plan showing how you can implement a five rights point of care barcode pilot in less than a week. If you Don't own MS Project 2003, then here is a PDF copy just to see.... Download Adobe PDF Data Sheet

View a PowerPoint Presentation of ADERS ®.





Current Patient Safety and Drug Safety Updates from the FDA


FDA Press Releases RSS Feed

FDA Roundup: April 26, 2024
Fri, 26 Apr 2024 15:08:58 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Approves New Treatment for Uncomplicated Urinary Tract Infections
Wed, 24 Apr 2024 13:32:13 EDT

  Today, the FDA approved a new treatment for female adults with uncomplicated urinary tract infections caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.

FDA Roundup: April 23, 2024
Tue, 23 Apr 2024 15:20:02 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Roundup: April 19, 2024
Fri, 19 Apr 2024 16:19:55 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Roundup: April 16, 2024
Tue, 16 Apr 2024 14:56:33 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Roundup: April 12, 2024
Fri, 12 Apr 2024 13:41:05 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Federal Court Enters Consent Decree Against Philips Respironics Following Recall of Certain Sleep Therapy Machines
Tue, 09 Apr 2024 15:44:38 EDT

  The federal court entered a consent decree of permanent injunction against Philips Respironics following a recall of certain sleep therapy machines manufactured by the company.

FDA Roundup: April 9, 2024
Tue, 09 Apr 2024 15:30:54 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Roundup: April 5, 2024
Fri, 05 Apr 2024 14:51:44 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Approves New Antibiotic for Three Different Uses
Wed, 03 Apr 2024 15:27:56 EDT

  The FDA approved a new antibiotic for the treatment of certain patients with Staphylococcus aureus bloodstream infections, including those with right-sided infective endocarditis; acute bacterial skin and skin structure infections; and community-acquired bacterial pneumonia.

FDA Roundup: April 2, 2024
Tue, 02 Apr 2024 16:37:54 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Roundup: March 29, 2024
Fri, 29 Mar 2024 15:19:41 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Roundup: March 26, 2024
Tue, 26 Mar 2024 15:37:03 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects
Tue, 26 Mar 2024 14:31:45 EDT

  FDA warns consumers not to use certain over-the-counter pain relief products containing lidocaine that are marketed for topical use in cosmetic procedures like microdermabrasion, laser hair removal, tattooing and piercing, and issued warning letters to six companies for violating of federal law.

FDA Roundup: March 22, 2024
Fri, 22 Mar 2024 16:45:27 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Approves Nonsteroidal Treatment for Duchenne Muscular Dystrophy
Thu, 21 Mar 2024 18:29:46 EDT

  The FDA approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older. Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD.

FDA Roundup: March 19, 2024
Tue, 19 Mar 2024 16:08:31 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Approves First Gene Therapy for Children with Metachromatic Leukodystrophy
Mon, 18 Mar 2024 13:52:03 EDT

  Lenmeldy is the first FDA-approved gene therapy indicated for the treatment of children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile metachromatic leukodystrophy (MLD).

FDA Roundup: March 15, 2024
Fri, 15 Mar 2024 16:47:37 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease
Thu, 14 Mar 2024 15:58:34 EDT

  The FDA approved the first medication for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring, to be used along with diet and exercise.

Food and Drugs Administration--Recalls/Safety Alerts

Tama Corporation Recalls Product Because of Possible Health Risk
Thu, 25 Apr 2024 00:00:00 EDT

  Tama Corporation of Doral FL is recalling 24-ounce containers of "Oueso de Mano PAISA" have contamination with Listeria monocytogenes, a bacterium that can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy indivi

Dr. Reddy’s Issues Voluntary Nationwide Recall of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg Due to Sub-Potency
Tue, 23 Apr 2024 13:02:00 EDT

  Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced that it is voluntarily recalling six (6) lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer leve

STOP CLOPEZ CORP Issues Voluntary Worldwide Recall of Schwinnng Capsules Due to the Presence of Undeclared Nortadalafil
Mon, 22 Apr 2024 11:30:00 EDT

  Hollywood, FL, US, STOP CLOPEZ CORP is voluntarily recalling one lot of Schwinnng capsules to the consumer level. FDA analysis has found the Schwinnng products to contain Nortadalafil. Nortadalafil is an active drug ingredient known for the treatment of male erectile dysfunction. The presence of Nor

Primal Kitchen Issues Voluntary Recall of Primal Kitchen Avocado Oil (750mL Glass) Due to Packaging Issue
Fri, 19 Apr 2024 12:20:00 EDT

  Primal Kitchen is announcing a voluntary recall of approximately 2,060 cases of three code dates of Primal Kitchen Avocado Oil (750mL) because the glass may be prone to breakage, causing the product to spill.

Infinite Herbs, LLC Expands Recall of Fresh Organic Basil to Include Melissa’s Brand Organic Basil Received by Illinois and Missouri Retailer
Fri, 19 Apr 2024 10:36:00 EDT

  Infinite Herbs LLC of Miami, Florida, is expanding its April 18th recall to include Melissa's brand fresh organic basil in 2.0 oz ( 96 packages, UPC 0 45255 14142 9) and 4.0 oz packages (24 packages, UPC 0 45255 14439 0) available for sale at Dierberg's stores in Illinois and Missouri between Febru

Sammy’s Milk Providing a Warning Against the Use of Goat Milk Toddler Formula as Infant Formula
Thu, 18 Apr 2024 20:24:00 EDT

  Newport Beach, California - Sammy's Milk, a local company, has been asked by the Food and Drug Administration (FDA) to provide a warning against the use of its Goat Milk Toddler Formula as an infant formula because the FDA is concerned that the formula may not meet all FDA requirements for infant fo

Infinite Herbs, LLC Voluntarily Recalls 2.5-Ounce Fresh Organic Basil Sold From February 1 Through April 6 Because of Possible Health Risk
Thu, 18 Apr 2024 10:09:00 EDT

  Infinite Herbs LLC of Miami, Florida, is voluntarily recalling 2.5-ounce packages of Infinite Herbs fresh organic basil sold between February 1 and April 6, 2024, and bearing the UPC 8 18042 02147 7 (see photos below) because they have the potential to be contaminated with Salmonella

Cargill Conducts Voluntary Recall of Nutrena® Country Feeds® Meatbird 22% Crumble Due to Non-inclusion of Vitamin D
Sat, 13 Apr 2024 14:00:00 EDT

  Cargill’s animal nutrition business is conducting a voluntary recall of Nutrena® Country Feeds® Meat bird 22% Crumble (RV) due to non-inclusion of Vitamin D. Lack of Vitamin D in meat bird diets can lead to mineral deficiencies and bone issues, including rickets in growing birds.

Roly Poly Bakery Issues Allergy Alert on Undeclared Egg Ingredient in Multigrain Bread
Fri, 12 Apr 2024 15:59:00 EDT

  Roly Poly Bakery of New Britain, CT is recalling its 20 ounce loafs of Roly Poly multigrain bread because the product contains undeclared egg product. People who have allergies to eggs run the risk of serious or life-threatening allergic reaction if they consume these products.

Gracie’s Kitchen Inc. Issues Allergy Alert on Undeclared Sesame and Wheat Allergens in “Broccoli Cutlets”
Fri, 12 Apr 2024 13:11:00 EDT

  Gracie’s Kitchens of New Haven, CT, is recalling its 20-ounce packages of "King Kullen Broccoli Cutlets with Bread Crumbs and Parmesan" because they may contain undeclared sesame and wheat. People who have allergies to sesame and wheat run the risk of serious or life-threatening allergic reaction if

Feel Good Foods Issues Voluntary Recall of Gluten-Free Cream Cheese Stuffed Mini Bagels
Fri, 12 Apr 2024 00:00:00 EDT

  Feel Good Foods is voluntarily recalling its Gluten-Free Plain and Everything flavored Cream Cheese Stuffed Mini Bagels. The products may contain undeclared gluten that may be present due to cross-contamination. People who have an allergy or severe sensitivity to gluten run the risk of serious aller

ADM Animal Nutrition Expands Recall to Include 17 Additional Lots of Chicken, Swine and Rabbit Feed Products
Thu, 11 Apr 2024 18:00:00 EDT

  Specific lots may contain elevated levels of magnesium, sodium, calcium and/or phosphorus; may harm chickens, swine, rabbits.

Oregon Spice Company Issues Allergy Alert on Undeclared Sesame in Johnny’s Parmesan Garlic Seasoning
Wed, 10 Apr 2024 19:24:00 EDT

  Oregon Spice Company, Portland, OR is recalling Johnny’s Parmesan Garlic Seasoning 5oz because it may contain undeclared sesame. People who have an allergy or severe sensitivity to sesame run the risk of serious or life-threatening allergic reaction if they consume this product.

Home Style Foods, Inc. Issues Allergy Alert on Undeclared Egg in Kowalski Simply Sides – Jack’s Potato Salad
Wed, 10 Apr 2024 12:40:00 EDT

  Home Style Foods, Inc., of Hamtramck, MI, is voluntarily recalling 43 cases of “Kowalski Simply Sides - Jack’s Potato Salad” due to an incorrect label resulting in an undeclared egg allergen. People who have an allergy or severe sensitivity to eggs run the risk of serious or life-threatening allerg

Belgian Yummies Issues Allergy Alert on Undeclared Allergens of Wheat, Soy, Egg, Coconut and/or Peanuts and FD&C Yellow #5 in Ice Cream Sandwiches and Gelato
Tue, 09 Apr 2024 17:10:00 EDT

  Belgian Yummies of Fort Myers, FL, is alerting the public that its 4-ounce packages of Ice Cream Sandwiches and 5-liter containers and 4.75-liter pans of Gelato contains undeclared allergens.

Baron Spices, Inc. Issues Allergy Alert on Undeclared Soy and Wheat in Blues Hog Sweet & Savory Seasoning
Tue, 09 Apr 2024 17:00:00 EDT

  Baron Spices, Inc. of St. Louis, MO is recalling 708 units of Blues Hog Sweet and Savory Seasoning, because it may contain undeclared Soy and Wheat allergen. People who have an allergy or severe sensitivity to Soy and Wheat run the risk of serious or life-threatening allergic reaction if they consum

Global Mix, Inc Recalls Tejocote Products Because of Possible Health Risk
Fri, 05 Apr 2024 17:22:00 EDT

  Global Mix, Inc. of New York, is recalling tejocote products to include the following brands: Eva Nutrition, Science of Alpha, Niwali, NWL Nutra. The recalled products are labeled as tejocote root but are toxic yellow oleander. Ingestion of yellow oleander can cause neurologic, gastrointestinal, an

Medline Industries, LP Issues a Nationwide Recall of Convenience Kits Containing Nurse Assist 0.9% Sodium Chloride Irrigation USP and Sterile Water for Irrigation USP
Fri, 05 Apr 2024 15:30:00 EDT

  Northfield, Ill., Apr. 5, 2024 – In direct response to the Nurse Assist, LLC voluntary product recall initiated on November 6, 2023, for saline and sterile water medical products, Medline Industries, LP initiated a nationwide recall on November 15, 2023, for its Medline and Centurion branded conveni

Aruba Aloe Balm N.V. Issues Voluntary Nationwide Recall of Aruba Aloe Hand Sanitizer Gel Alcohol 80% and Aruba Aloe Alcoholada Gel Due to Presence of Methanol
Fri, 05 Apr 2024 13:14:00 EDT

  Oranjestad, Aruba, Aruba Aloe Balm N.V. is voluntarily recalling 40 lots of Aruba Aloe Hand Sanitizer Gel Alcohol 80% and Aruba Aloe Alcoholada Gel to the consumer level. The products have been found to contain alcohol denatured with methanol.


Honeywell Safety Products USA, Inc. Issues Voluntary Worldwide Recall of Honeywell Fendall 2000 Non-Sterile Eyewash Cartridges # 32-002050-0000 used with the Fendall 2000 Eyewash Station Due to a Lack of Appropriate Policies and Procedures by Honeywell’s Supplier
Thu, 04 Apr 2024 00:00:00 EDT

  Charlotte, NC, Honeywell Safety Products USA, Inc. is voluntarily recalling Fendall 2000 Non-Sterile Eyewash Cartridge for the Fendall 2000 Eyewash Station. This recall is being conducted at the industrial consumer level. Honeywell’s supplier of the Fendall 2000 Non-Sterile Eyewash Cartridge has bee

What's New: Drugs RSS Feed

What's New Related to Drugs
Fri, 26 Apr 2024 17:21:03 EDT

  Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

Non-Compliance Letters under 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act
Fri, 26 Apr 2024 16:23:57 EDT

  Section 505B(d)(1) requires FDA to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA by the final due date, have failed to seek or obtain a deferral or deferral extension, or have failed to request approval for a required pediatri

FDA Roundup: April 26, 2024
Fri, 26 Apr 2024 15:08:58 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Important Addresses for Regulatory Submissions
Fri, 26 Apr 2024 14:36:46 EDT

  Important Addresses for Regulatory Submissions

Drug Application Process for Nonprescription Drugs
Fri, 26 Apr 2024 14:11:21 EDT

  There are two regulatory pathways to bring a nonprescription drug to market in the U.S. -- the drug application process and Over-the-Counter (OTC) Drug Review (OTC monograph) process.

Therapeutic Biologics Applications (BLA)
Fri, 26 Apr 2024 14:07:50 EDT

  Therapeutic Biologics Applications (BLA)

List of Determinations Including Written Request
Fri, 26 Apr 2024 14:04:38 EDT

  In accordance with section 505A(e)(1) of the Act, as amended by FDAAA (Pub. L. No. 110-85), the following list identifies those approved drugs for which a pediatric exclusivity determination was made, on or after September 27, 2007.

Competitive Generic Therapy Approvals
Fri, 26 Apr 2024 13:56:33 EDT

  A list of all FDA-approved abbreviated new drug applications for drug products that received a Competitive Generic Therapy designation under section 506H of the Federal Food, Drug, and Cosmetic Act.

We Are Hiring
Fri, 26 Apr 2024 13:46:13 EDT

  FDA/CDER employment opportunities utilizing the FDA 21st Century Cures Act Hiring Authority

Patent Certifications and Suitability Petitions
Fri, 26 Apr 2024 13:44:29 EDT

  Information on patents and suitability petitions that impact the availability of generic drugs.

Recently Issued Guidance Documents
Fri, 26 Apr 2024 13:42:54 EDT

  This page lists Recently Issued CBER and Cross-Center Guidance Documents.

Impact Stories
Fri, 26 Apr 2024 13:28:29 EDT

  Stories illustrating how regulatory science impacts the lives and health of people


How physicians interpret information about prescription drugs in scientific publications vs. promotional pieces
Fri, 26 Apr 2024 13:21:10 EDT

  How physicians interpret information about prescription drugs in scientific publications vs. promotional pieces

Drug Development Considerations for Empiric Antibacterial Therapy in Febrile Neutropenic Patients - 04/23/2024
Fri, 26 Apr 2024 13:20:11 EDT

  The purpose of the public workshop is to discuss clinical trial design and other considerations related to the development of antibacterial drug products for treatment of febrile neutropenia (FN).

2024 Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments - 06/06/2024
Fri, 26 Apr 2024 13:19:34 EDT

  The Food and Drug Administration (FDA or the Agency) is announcing its annual public meeting and opportunity for public comment on “Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments.”

Generic Drug Facilities, Sites and Organization Lists
Fri, 26 Apr 2024 10:02:38 EDT

  Generic Drug Facilities, Sites and Organization Lists

User Fee Lists
Fri, 26 Apr 2024 10:00:58 EDT

  Fiscal Year (FY) 2017 GDUFA facility fees are due on October 3, 2016.

A Milestone in Facilitating the Development of Safe and Effective Biosimilars
Fri, 26 Apr 2024 09:49:31 EDT

  The 50th biosimilar approval milestone also reflects our strategic approach to biosimilars, as outlined in the FDA’s Biosimilars Action Plan.

Peptides, proteins, and the risks of cardiac arrythmias: A CDER study suggests that the human Thorough QT study is not needed for products comprised of naturally occurring amino acids
Fri, 26 Apr 2024 09:29:33 EDT

  Peptides, proteins, and the risks of cardiac arrythmias: a CDER study suggests that the human Thorough QT study is not needed for products comprised of naturally occurring amino acids

Antimicrobial Resistance Information from FDA
Fri, 26 Apr 2024 09:23:21 EDT

  Antimicrobial resistance (AMR)—the ability of a microorganism (bacteria, virus, fungi, parasite) to resist the effects of a drug—is a serious, complex and costly public health problem. Learn what FDA is doing to address AMR.

Whats New Vaccines Blood Biologics RSS Feed

Licensed Biological Products with Supporting Documents
Fri, 26 Apr 2024 17:38:15 EDT

  Licensed biological products with supporting documents is arranged alphabetically by the proper name of the product(s). Information is provided for original product approvals, new indications, and the current package insert.

What’s New for Biologics
Fri, 26 Apr 2024 17:27:23 EDT

  Latest news from the Center for Biologics Evaluation and Research

Approved Cellular and Gene Therapy Products
Fri, 26 Apr 2024 16:11:22 EDT

  Listing of licensed and approved products from the Office of Tissues and Advanced Therapies (OTAT).

BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies: FDA Safety Communication - FDA Investigating Serious Risk of T-cell Malignancy
Fri, 26 Apr 2024 15:25:56 EDT

  The FDA has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.

FDA Roundup: April 26, 2024
Fri, 26 Apr 2024 15:08:58 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Important Information for Human Cell, Tissue, and Cellular and Tissue-based Product (HCT/P) Establishments Regarding the Recall of Certain Saline and Sterile Water Medical Products by Nurse Assist
Fri, 26 Apr 2024 14:29:16 EDT

  The FDA is advising establishments that manufacture HCT/Ps about a recall of products that may have been used in manufacturing. FDA is posting this information in response to questions about the recall.

Recently Issued Guidance Documents
Fri, 26 Apr 2024 13:42:54 EDT

  This page lists Recently Issued CBER and Cross-Center Guidance Documents.

Clinical Guidances
Fri, 26 Apr 2024 13:42:47 EDT

  This page lists Clinical Guidance documents.

Antimicrobial Resistance Information from FDA
Fri, 26 Apr 2024 09:23:21 EDT

  Antimicrobial resistance (AMR)—the ability of a microorganism (bacteria, virus, fungi, parasite) to resist the effects of a drug—is a serious, complex and costly public health problem. Learn what FDA is doing to address AMR.

KYMRIAH
Thu, 25 Apr 2024 18:27:01 EDT

  KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse

TECARTUS
Thu, 25 Apr 2024 18:07:07 EDT

  For the treatment of adult patients with relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia (B-ALL). For the treatment of adult patients with relapsed/refractory mantle cell lymphoma (r/r MCL).

YESCARTA
Thu, 25 Apr 2024 17:55:52 EDT

  For the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Axicabtagene ciloleucel is not indicated for the treatment of patients with primary central nervous system lymphoma.

Biologics Electronic Reading Room (eFOIA)
Thu, 25 Apr 2024 14:45:55 EDT

  The Biologics eFOI Reading Room provides access to documents posted throughout the "Vaccines, Blood & Biologics" and other sections related to the Center for Biologics Evaluation and Research on the FDA.gov Web site.

Combating Antibiotic Resistance
Thu, 25 Apr 2024 13:50:28 EDT

  Misuse and overuse of antibiotics have contributed to antibiotic resistance, a phenomenon that reduces or eliminates the effectiveness of antibiotics

Jobs at the Center for Biologics Evaluation and Research (CBER)
Thu, 25 Apr 2024 09:51:25 EDT

  CBER has unique opportunities for individuals with backgrounds in science or administration to fill positions involved in the regulation and research of blood, vaccines and therapeutics.

Health Fraud Scams
Wed, 24 Apr 2024 21:08:15 EDT

  Learn how to spot health fraud and avoid it.

Testing Human Cells, Tissues, and Cellular and Tissue Based Product (HCT/P) Donors for Relevant Communicable Disease Agents and Diseases
Wed, 24 Apr 2024 13:50:24 EDT

  Testing HCT/P Donors for Relevant Communicable Diseases

FDA CBER Webinar: Considerations for the Development of CAR T Cell Products - 03/07/2024
Wed, 24 Apr 2024 12:09:11 EDT

  The FDA Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products (OTP) is hosting a virtual public webinar on Thursday, March 7 at 1:00 p.m.

Roster of the Blood Products Advisory Committee
Wed, 24 Apr 2024 10:05:49 EDT

  This is the Roster of the Blood Products Advisory Committee (BPAC).

Labeling and Promotion Guidances
Wed, 24 Apr 2024 10:03:57 EDT

  This page lists Labeling and Promotion Guidance documents.





See how to prevent medication errors with bar codes using ADERS. Get your free pilot started today.






Products



 
 

Services




Contact Us


About PCS


Corporate Headquarters


Practical Compliance Solutions
One Orient Way
Suite F156
Rutherford, NJ 07070
  201-728-8809


40.827731 N 74.101029 W

Connect With Us

   
 
 
© 2002 - 2024 - Copyright Practical Compliance Solutions - All rights reserved